Ann: Date of Annual General Meeting, page-8

Hey Straw, your still in the game. I would average down at this point because the product is good, its the companies arrogance to risk approvals by taking short cuts. But they will do it properly now and the company will be worth many multiples of where it is now once the product is approved and being used in hospitals across the world.

The journey has been made alot longer by ill-conceived planning but the destination is still on the horizon and it will be worth it when u get there. Average down.